AR016217A1 - Composicion farmaceutica que comprende un modulador dispositivo de un agonista receptor nicotinico, metodo para el tratamiento de un trastorno asociado conuna transmision reducida de nicotina, metodo para identificar un agonista repector nicotinico, uso de un modulador positivo de un agonista recept - Google Patents
Composicion farmaceutica que comprende un modulador dispositivo de un agonista receptor nicotinico, metodo para el tratamiento de un trastorno asociado conuna transmision reducida de nicotina, metodo para identificar un agonista repector nicotinico, uso de un modulador positivo de un agonista receptInfo
- Publication number
- AR016217A1 AR016217A1 ARP990101861A ARP990101861A AR016217A1 AR 016217 A1 AR016217 A1 AR 016217A1 AR P990101861 A ARP990101861 A AR P990101861A AR P990101861 A ARP990101861 A AR P990101861A AR 016217 A1 AR016217 A1 AR 016217A1
- Authority
- AR
- Argentina
- Prior art keywords
- nicotinic
- treatment
- pharmaceutical composition
- agonist
- repector
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Addiction (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Composicion farmacéutica que comprende un modulador positivo de un agonista receptor nicotínico (por ejemplo, 5-hidroxiindol (5-Ohi) conjuntamente con unportador farmacéuticamente aceptable, teniendo dicho modulador positivo la capacidad de incrementar la eficacia de dicho agonista receptor nicotínico. Métodopara el tratamiento de un trastorno asociado con una transmision reducida de nicotina, método para identificar un agonista receptor nicotínico, uso de unmodulador positivo de un agonista receptor nicotínico en la manufacrtura de un medicamento para el tratamiento de o para la profilaxis de un trastorno asociadocon una transmision de nicotina reducida, en la manufactura de un medicamento para el tratamiento del mal de Alzheimer, desordenes de hiperactividad de déficitde atencion, esquizofrenia, ansiedad o adicion a la nicotina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/071,826 US6277870B1 (en) | 1998-05-04 | 1998-05-04 | Use |
Publications (1)
Publication Number | Publication Date |
---|---|
AR016217A1 true AR016217A1 (es) | 2001-06-20 |
Family
ID=22103848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990101861A AR016217A1 (es) | 1998-05-04 | 1999-04-22 | Composicion farmaceutica que comprende un modulador dispositivo de un agonista receptor nicotinico, metodo para el tratamiento de un trastorno asociado conuna transmision reducida de nicotina, metodo para identificar un agonista repector nicotinico, uso de un modulador positivo de un agonista recept |
Country Status (27)
Country | Link |
---|---|
US (2) | US6277870B1 (es) |
EP (1) | EP1079828B1 (es) |
JP (1) | JP2002513757A (es) |
KR (1) | KR20010043266A (es) |
CN (2) | CN1637149A (es) |
AR (1) | AR016217A1 (es) |
AT (1) | ATE249827T1 (es) |
AU (1) | AU770849B2 (es) |
BR (1) | BR9910180A (es) |
CA (1) | CA2331070A1 (es) |
DE (1) | DE69911400T2 (es) |
EE (1) | EE200000640A (es) |
HK (1) | HK1034205A1 (es) |
HU (1) | HUP0102504A3 (es) |
ID (1) | ID27289A (es) |
IL (1) | IL139145A0 (es) |
IS (1) | IS5699A (es) |
MY (1) | MY116027A (es) |
NO (1) | NO20005503L (es) |
PL (1) | PL343923A1 (es) |
RU (1) | RU2225203C2 (es) |
SK (1) | SK284608B6 (es) |
TR (1) | TR200003244T2 (es) |
TW (1) | TW542718B (es) |
UA (1) | UA65617C2 (es) |
WO (1) | WO1999056745A1 (es) |
ZA (1) | ZA200006133B (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277870B1 (en) | 1998-05-04 | 2001-08-21 | Astra Ab | Use |
US20040259909A1 (en) * | 2001-10-16 | 2004-12-23 | Mccarthy Dennis | Treatment of fibromyalgia syndrome |
PL374384A1 (en) * | 2001-12-14 | 2005-10-17 | Targacept, Inc. | Methods and compositions for treatment of central nervous system disorders |
US7091357B2 (en) * | 2001-12-26 | 2006-08-15 | University Of Kentucky Research Foundation | Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies |
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
US20040052928A1 (en) * | 2002-09-06 | 2004-03-18 | Ehud Gazit | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
US7781396B2 (en) | 2002-01-31 | 2010-08-24 | Tel Aviv University Future Technology Development L.P. | Peptides directed for diagnosis and treatment of amyloid-associated disease |
US20030162770A1 (en) | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
US20030236287A1 (en) * | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
EP1502110A4 (en) | 2002-05-09 | 2007-09-05 | Memory Pharm Corp | QM-7 AND QT-6 CELLS TRANSFECTED WITH MUTANT CHANNEL RECEPTORS WITH SURFACE EXPRESSION AND TESTS USING THESE TRANSFECTED CELLS |
EP1531820A1 (en) | 2002-08-30 | 2005-05-25 | Memory Pharmaceuticals Corporation | Anabaseine derivatives useful in the treatment of neurodegenerative diseases |
RU2391341C2 (ru) | 2002-09-25 | 2010-06-10 | Мемори Фармасьютиклз Корпорейшн | Индазолы, бензотиазолы, бензоизотиазолы, их получение и применение |
US7491699B2 (en) | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
EP2058275A1 (en) | 2003-01-07 | 2009-05-13 | Ramot at Tel-Aviv University Ltd. | Peptide nanostructures encapsulating a foreign material and method of manufacturing same |
CA2540407A1 (en) | 2003-09-25 | 2005-03-31 | Tel Aviv University Future Technology Development L.P. | Compositions and methods using same for treating amyloid-associated diseases |
US7625707B2 (en) * | 2003-10-02 | 2009-12-01 | Ramot At Tel Aviv University Ltd. | Antibacterial agents and methods of identifying and utilizing same |
PT1697378E (pt) | 2003-12-22 | 2008-02-28 | Memory Pharm Corp | Indoles, 1h-indazoles, 1,2-benzisoxazoles e 1,2-benzisotiazoles, sua preparação e utilizações |
NZ550534A (en) | 2004-03-25 | 2009-07-31 | Memory Pharm Corp | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
CA2567977A1 (en) | 2004-04-22 | 2006-01-05 | Memory Pharmaceutical Corporation | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof |
EP1745046B1 (en) | 2004-05-07 | 2011-04-13 | Memory Pharmaceuticals Corporation | 1 h-indazoles, benzothiazoles, 1,2-benziosoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof |
WO2006006172A2 (en) * | 2004-07-15 | 2006-01-19 | Ramot At Tel Aviv University Ltd. | Use of anti-amyloid agents for treating and typing pathogen infections |
US8568637B2 (en) * | 2004-08-02 | 2013-10-29 | Ramot At Tel-Aviv University Ltd. | Method of forming a fiber made of peptide nanostructures |
EP1793816B1 (en) | 2004-08-19 | 2012-01-04 | Tel Aviv University Future Technology Development L.P. | Compositions for treating amyloid associated diseases |
US7786086B2 (en) * | 2004-09-08 | 2010-08-31 | Ramot At Tel-Aviv University Ltd. | Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same |
AU2005319248A1 (en) | 2004-12-22 | 2006-06-29 | Memory Pharmaceuticals Corporation | Nicotinic alpha-7 receptor ligands and preparation and uses thereof |
CN101247853B (zh) | 2005-04-13 | 2014-11-12 | 轴突公司 | 具有nos抑制活性的取代的吲哚化合物 |
US8106066B2 (en) | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
US10004828B2 (en) * | 2005-10-11 | 2018-06-26 | Romat at Tel-Aviv University Ltd. | Self-assembled Fmoc-ff hydrogels |
US7879212B2 (en) * | 2005-11-03 | 2011-02-01 | Ramot At Tel-Aviv University Ltd. | Peptide nanostructure-coated electrodes |
US20070134169A1 (en) * | 2005-12-11 | 2007-06-14 | Rabinoff Michael D | Methods for smoking cessation or alcohol cessation or other addiction cessation |
AR060451A1 (es) * | 2006-04-13 | 2008-06-18 | Neuraxon Inc | Compuestos de indol 1,5 y 3,6-sustituidos con actividad inhibitoria de nos |
US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
AU2008321353A1 (en) * | 2007-11-16 | 2009-05-22 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for treating visceral pain |
NZ586082A (en) * | 2007-11-16 | 2013-03-28 | Neuraxon Inc | Indole compounds and methods for treating visceral pain |
TR201807944T4 (tr) | 2008-11-19 | 2018-06-21 | Forum Pharmaceuticals Inc | (R)-7-kloro-N-(kinüklidin-3-il)benzo[b]tiyofen-2-karboksamit ve bunun farmasötik olarak kabul edilebilir tuzları ile şizofreninin negatif belirtilerinin tedavisi. |
JP5808319B2 (ja) * | 2009-05-11 | 2015-11-10 | フォルム ファーマシューティカルズ、インコーポレイテッド | アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα7ニコチン酸受容体を用いた認知障害の治療 |
ES2746850T3 (es) | 2010-05-17 | 2020-03-09 | Forum Pharmaceuticals Inc | Formulaciones farmacéuticas que comprenden formas cristalinas de clorhidrato de (R)-7-cloro-N-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida monohidratado |
SG188307A1 (en) | 2010-09-23 | 2013-04-30 | Abbvie Inc | Monohydrate of an azaadamantane derivative |
MX358512B (es) | 2012-05-08 | 2018-08-24 | Forum Pharmaceuticals Inc | Uso de (r)-7cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma para preparar una composición farmacéutica en el tratamiento de una disfunción cognitiva. |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2649009B1 (fr) * | 1989-07-03 | 1991-10-11 | Oreal | Procede de teinture des fibres keratiniques a base de monohydroxyindole et de 5,6-dihydroxyindole et composition mise en oeuvre |
US5272155A (en) * | 1991-12-05 | 1993-12-21 | Abbott Laboratories | (+)-2-methylpiperidine as modulator of cholinergic systems |
AU701227B2 (en) * | 1993-09-10 | 1999-01-21 | Cytomed, Inc | Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists |
HUT77352A (hu) * | 1994-08-24 | 1998-03-30 | Astra Aktiebolag | Spiro[aza-bicikloalkán-oxazolidin]-2'-on-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények |
SE9600683D0 (sv) * | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
AR013184A1 (es) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
US6277870B1 (en) | 1998-05-04 | 2001-08-21 | Astra Ab | Use |
-
1998
- 1998-05-04 US US09/071,826 patent/US6277870B1/en not_active Expired - Fee Related
-
1999
- 1999-04-21 TW TW088106373A patent/TW542718B/zh not_active IP Right Cessation
- 1999-04-22 AR ARP990101861A patent/AR016217A1/es unknown
- 1999-04-28 EE EEP200000640A patent/EE200000640A/xx unknown
- 1999-04-28 AT AT99948542T patent/ATE249827T1/de not_active IP Right Cessation
- 1999-04-28 DE DE69911400T patent/DE69911400T2/de not_active Expired - Fee Related
- 1999-04-28 PL PL99343923A patent/PL343923A1/xx not_active Application Discontinuation
- 1999-04-28 CN CNA2004100880671A patent/CN1637149A/zh active Pending
- 1999-04-28 AU AU43023/99A patent/AU770849B2/en not_active Ceased
- 1999-04-28 WO PCT/SE1999/000700 patent/WO1999056745A1/en not_active Application Discontinuation
- 1999-04-28 HU HU0102504A patent/HUP0102504A3/hu unknown
- 1999-04-28 BR BR9910180-7A patent/BR9910180A/pt not_active IP Right Cessation
- 1999-04-28 SK SK1570-2000A patent/SK284608B6/sk unknown
- 1999-04-28 RU RU2000130209/15A patent/RU2225203C2/ru not_active IP Right Cessation
- 1999-04-28 CN CN99805760A patent/CN1299279A/zh active Pending
- 1999-04-28 EP EP99948542A patent/EP1079828B1/en not_active Expired - Lifetime
- 1999-04-28 CA CA002331070A patent/CA2331070A1/en not_active Abandoned
- 1999-04-28 JP JP2000546771A patent/JP2002513757A/ja active Pending
- 1999-04-28 IL IL13914599A patent/IL139145A0/xx unknown
- 1999-04-28 KR KR1020007012221A patent/KR20010043266A/ko not_active Application Discontinuation
- 1999-04-28 TR TR2000/03244T patent/TR200003244T2/xx unknown
- 1999-04-28 UA UA2000126907A patent/UA65617C2/uk unknown
- 1999-05-04 MY MYPI99001750A patent/MY116027A/en unknown
- 1999-05-28 ID IDW20002260A patent/ID27289A/id unknown
-
2000
- 2000-10-30 ZA ZA200006133A patent/ZA200006133B/en unknown
- 2000-11-01 IS IS5699A patent/IS5699A/is unknown
- 2000-11-01 NO NO20005503A patent/NO20005503L/no not_active Application Discontinuation
-
2001
- 2001-03-20 US US09/812,269 patent/US6861443B2/en not_active Expired - Fee Related
- 2001-07-17 HK HK01105008A patent/HK1034205A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR016217A1 (es) | Composicion farmaceutica que comprende un modulador dispositivo de un agonista receptor nicotinico, metodo para el tratamiento de un trastorno asociado conuna transmision reducida de nicotina, metodo para identificar un agonista repector nicotinico, uso de un modulador positivo de un agonista recept | |
MX9203444A (es) | Medicamentos. | |
CO5011096A1 (es) | Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs | |
TNSN01053A1 (fr) | Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique | |
UY26693A1 (es) | Una composición farmacéutica y procedimiento de tratamiento de enfermedades de disfunción cognitiva en un mamífero | |
BR0200283A (pt) | Composições farmacêuticas para o tratamento de distúrbios do snc e de outros distúrbios | |
BR0112054A (pt) | Composição formadora de micelas, e métodos para a administração e a proteção de um agente terapêutico | |
DK0740650T3 (da) | Codrugs som metode til styret transport af lægemiddel | |
NO993520D0 (no) | Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon | |
AR019246A1 (es) | Agonistas de receptores de 5-ht1 y metoclopramida para el tratamiento de la migrana. | |
AR026610A1 (es) | Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central | |
BG108131A (en) | Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders | |
ATE260646T1 (de) | Schnell zerfallende orale dosierungsform | |
BR0205722A (pt) | Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor | |
BR9909277A (pt) | Compostos com atividade em receptores muscarìnicos | |
DK1135153T3 (da) | Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser | |
BR0113980A (pt) | Compostos de succinimida heterocìclicos fundidos e seus análogos, moduladores de função de receptor de hormÈnio nuclear | |
CL2008003941A1 (es) | Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden compulsivo obsesivo. | |
BRPI0410807A (pt) | composição farmacêutica, e, método pata tratar um mamìfero sofrendo de ou susceptìvel a condições associadas com dor cefálica | |
AR033179A1 (es) | Combinacion de farmacos para inhalacion | |
NO20004419L (no) | Ny anvendelse | |
DE59813162D1 (de) | Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen | |
FI962550A0 (fi) | Deuterisoidut vaikuttavat aineet transdermaalisessa käyttötarkoituksessa | |
BR0211855A (pt) | Medicamento e método para tratamento e melhoria da qualidade restauradora do sono | |
BR0104345A (pt) | Tratamento combinado para a depressão e ansiedade |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |